Simona Casalino

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Journal: NPJ precision oncology

Published: May 22, 2026

CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma.

CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma.

Journal: Translational oncology

Published: April 10, 2026

Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma.

Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial.

Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 12, 2025

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.

Journal: The oncologist

Published: October 07, 2025

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

Journal: ESMO open

Published: October 03, 2025

EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages.

EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages.

Journal: Oncogene

Published: August 14, 2025

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma.

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 28, 2024

CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Journal: NPJ precision oncology

Published: April 24, 2024

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 17, 2023

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.

Journal: Therapeutic advances in medical oncology

Published: August 09, 2023

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.

Journal: Journal of personalized medicine

Published: May 02, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026